MNMakoto Nakamuta

Makoto Nakamuta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Makoto Nakamuta has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Hajime Nawata

    8 shared publications
  • Munechika Enjoji

    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    7 shared publications
  • Kazuhiro Kotoh

    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    5 shared publications
  • Hiroaki Iwamoto

    Department of Medicine and Bioregulatory Science and † Department of Pathophysiological and Experimental Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    4 shared publications
  • Motoyuki Kohjima

    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    4 shared publications
  • Hironori Sakai

    Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

    3 shared publications

Latest Publications

  • Successful Treatment of Advanced-stage Autoimmune Pancreatitis-related Sclerosing Cholangitis

    by Ken Kawabe, Tetsuhide Ito, Yoshiyuki Arita, Makoto Nakamuta, Hajime Nawata, Ryoichi Takayanagi


  • Evaluation of liver parenchymal pressure and portal endothelium damage during radio frequency ablation in an in vivo porcine model

    by Kazuhiro Kotoh, Shusuke Morizono, Motoyuki Kohjima, Munechika Enjoji, Hironori Sakai, Makoto Nakamuta

    Abstract: Background/Aims: We previously developed a multi‐step, incremental expansion method (multi‐step method) for radio frequency ablation (RFA) in vitro, which prevented increases in pressure and reduced the ablation time as compared with other methods. In this study, we evaluated liver parenchymal pressure and portal endothelium damage during RFA with different devices and protocols in an in vivo porcine model.Method: Nine healthy female pigs were anaesthetized. RFA was performed with two different devices and protocols; one involved the use of a LeVeen needle with a single‐step full expansion method or a multi‐step method, and the other used a cool‐tip needle with 40 or 60 W power. We measured the pressure in the liver parenchyma and the gallbladder during RFA. We also evaluated portal endothelium damage by NADH staining.Results: The multi‐step method with the LeVeen electrode resulted in the lowest parenchymal and intra‐gallbladder pressures (multi‐step methodConclusion: Ablation with the LeVeen needle, especially when used with a multi‐step protocol, produced less of an increase in liver parenchymal and intra‐gallbladder pressures and less damage to portal endothelial cells than did the cool‐tip electrode.


  • Beraprost sodium, a prostacyclin (PGI2) analogue, ameliorates concanavalin A‐induced liver injury in mice

    by Satoshi Ohta, Makoto Nakamuta, Marie Fukushima, Motoyuki Kohjima, Kazuhiro Kotoh, Munechika Enjoji, Hajime Nawata

    Abstract: Background/Aims: Prostacyclin (PGI2) is a potent mediator in the inflammatory and coagulation processes. The aim of this study was to test whether beraprost sodium, a PGI2 analogue, could prevent experimental hepatic injury induced by concanavalin A (Con A), which is a model of fulminant hepatic failure.Methods: Beraprost (100 μg/kg) was administered intraperitoneally simultaneously with Con A (40 mg/kg) in C57B6J mice. Blood circulation in the liver was determined by laser‐Doppler flowmetry. Plasma levels of alanine aminotransferase (ALT), tumor necrosis factor (TNF)‐α, interferon (IFN)‐γ, and interleukin (IL)‐6 were determined. Levels of TNF‐α and IFN‐γ in culture supernatant of splenocytes were also determined.Results: Beraprost administration reduced the incidence of death following hepatic failure (76.5% vs. 29.4%, PIn vitro, beraprost also suppressed Con A‐induced TNF‐α production in splenocytes, while it stimulated IFN‐γ production.Conclusion: These findings imply that beraprost suppresses Con A‐induced liver injury. These data also suggest that beraparost, which is clinically effective in treating pulmonary hypertension, may have therapeutic potential for preventing hepatic injury.


  • Fasudil hydrochloride hydrate, a Rho‐kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells

    by Marie Fukushima, Makoto Nakamuta, Motoyuki Kohjima, Kazuhiro Kotoh, Munechika Enjoji, Naoya Kobayashi, Hajime Nawata

    Abstract: Background/Aims: The Rho–ROCK signaling pathways play an important role in the activation of hepatic stellate cells (HSCs). We investigated the effects of fasudil hydrochloride hydrate (fasudil), a Rho‐kinase (ROCK) inhibitor, on cell growth, collagen production, and collagenase activity in HSCs.Methods: Rat HSCs and human HSC‐derived TWNT‐4 cells were cultured for studies on stress fiber formation and α‐smooth muscle actin (α‐SMA) expression. Proliferation was measured by BrdU incorporation, and apoptosis by TUNEL assay. The phosphorylation states of the MAP kinases (MAPKs), extra cellular signal –regulated kinase 1/2 (ERK1/2), c‐jun kinase (JNK), and p38 were evaluated by western blot analysis. Type I collagen, matrix metalloproteinase‐1 (MMP‐1) and tissue inhibitor of matrix metalloproteinase‐1 (TIMP‐1) production and gene expression were evaluated by ELISA and real‐time PCR, respectively. Collagenase activity (active MMP‐1) was also evaluated.Results: Fasudil (100 μM) inhibited cell spreading, the formation of stress fibers, and expression of α‐SMA with concomitant suppression of cell growth, although it did not induce apoptosis. Fasudil inhibited phosphorylation of ERK1/2, JNK, and p38. Treatment with fasudil suppressed the production and transcription of collagen and TIMP, stimulated the production and transcription of MMP‐1, and enhanced collagenase activity.Conclusion: These findings demonstrated that fasudil not only suppresses proliferation and collagen production but also increases collagenase activity.


  • A multi‐step, incremental expansion method for radio frequency ablation: optimization of the procedure to prevent increases in intra‐tumor pressure and to reduce the ablation time

    by Kazuhiro Kotoh, Makoto Nakamuta, Shusuke Morizono, Motoyuki Kohjima, Eiichirou Arimura, Marie Fukushima, Munechika Enjoji, Hironori Sakai, Hajime Nawata

    Abstract: Background/Aims: Radio frequency ablation (RFA) has been accepted clinically as a useful local treatment for hepatocellular carcinoma (HCC). However, intra‐hepatic recurrence after RFA has been reported. We initially hypothesized that recurrence was attributable to increases in intra‐tumor pressure during RFA, and we subsequently measured the pressure and optimized the procedure.Methods: A block of pig liver sealed in a rigid plastic case was used as a model of an HCC tumor with a capsule. We compared the pressure between a single‐step full expansion of the needle (single‐step method) and incremental, stepwise expansion (multi‐step method), and evaluated the effect of varying the electrical power. Finally, we performed a preliminary comparison of the ablation times for these methods in HCC cases.Results: The multi‐step method resulted in a significantly lower pressure and shorter total ablation time than the single‐step method. Furthermore, incremental expansion in 10 steps resulted in a lower pressure and shorter ablation time than four steps. Seventy W‐ablation resulted in a lower pressure and shorter time than 30‐ or 50 W‐ablation. In HCC cases, the multiple‐step method had a significantly shorter ablation time than the single‐step method.Conclusion: The multi‐step method can be recommended to reduce the ablation time, and suppress the increase in pressure.


  • Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In Rats

    by Seiya Tada, Makoto Nakamuta, Munechika Enjoji, Rie Sugimoto, Hiroaki Iwamoto, Masaki Kato, Yutaka Nakashima, Hajime Nawata

    SUMMARY: 1. In the present study, we investigated the preventive effects of pirfenidone (PFD), an antifibrotic agent, on experimental hepatic fibrosis induced by dimethylnitrosamine (DMN) in rats.2. Treatment with DMN caused a significant decrease in bodyweight and liver weight. Oral PFD (500 mg/kg daily for 4 weeks) essentially prevented this DMN‐induced loss in bodyweight and tended to suppress the loss in liver weight. There were no significant differences in liver weight and serum L‐alanine aminotransferase levels between PFD‐treated and ‐untreated groups. Pirfenidone has no major side effects in vivo.3. Pirfenidone suppressed the induction of hepatic fibrosis determined by histological evaluation and reduced hepatic hydroxyproline levels. Expression of mRNA for type I collagen and transforming growth facter‐β in the liver was also suppressed by PFD treatment.4. Because hepatic stellate cells (HSC) are the major cellular source of extracellular matrix in hepatic fibrosis, we examined the effects of PFD on type I collagen production in vitro using rat primary HSC cultures. Pirfenidone inhibited collagen production in HSC culture in a dose‐dependent manner.5. These results demonstrate that the inhibitory effects of PFD against hepatic fibrosis may be due, at least in part, to blockade of collagen production by HSC and suggest that PFD may be potentially useful in the prevention of the development of hepatic fibrosis.


  • Prevalence of hepatitis B or C virus infections in patients with non‐Hodgkin's lymphoma

    by Masami Kuniyoshi, Makoto Nakamuta, Hironori Sakai, Munechika Enjoji, Naoko Kinukawa, Kazuhiro Kotoh, Marie Fukutomi, Masaki Yokota, Hidehiro Nishi, Hiroaki Iwamoto, et al.

    Background: Hepatitis C virus (HCV) and hepatitis B virus (HBV) are not only hepatotropic, but also lymphotropic viruses. Recently, some reports suggested that these viruses may participate in the development of malignant lymphoproliferative disorders.Methods: We investigated the prevalence of HCV or HBV infection in 348 patients with non‐Hodgkin's lymphoma (NHL). We also compared these prevalences with those in blood donors as a control group representing the general population in our area (n = 1 513 358). Next, we evaluated the clinical and pathologic characteristics of HCV‐ or HBV‐infected NHL cases. Non‐Hodgkin's lymphoma was classified according to the Working Formulation classification.Results: Thirty‐seven cases (14.9%) were found to be infected with HCV or HBV; of these, 20 (8.1%) were infected with HCV, and 17 (6.9%) with HBV. In male NHL patients, the rate of HCV infection was significantly higher than in an age‐ and sex‐matched population in the same area (P < 0.001, Mantel– Haenszel test). The rate of HBV infection also tended to be higher in the population (P = 0.0551). In contrast, in female NHL patients, the rate of HCV or HBV infection was not higher than in the general population. In HCV‐infected cases, 15 cases (75%) had B‐cell NHL and 16 cases (80%) were classified as being in the intermediate grade; B‐cell NHL comprised 83% of all NHL cases. In HBV‐infected NHL cases, 11 (65%) were of B‐cell type and 10 (58%) were classified as being in the intermediate grade.Conclusions: The high prevalence of HCV or HBV infections in our study population provides epidemiologic evidence suggesting that HCV and HBV infections may be involved in the development of a subgroup of NHL in males. Our investigation also revealed that both HCV‐ and HBV‐infected NHL patients showed certain similarities in clinical and pathologic manifestations.


  • Activation of Retinoic X Receptor and Peroxisome Proliferator-Activated Receptor–γ Inhibits Nitric Oxide and Tumor Necrosis Factor–α Production in Rat Kupffer Cells

    by Koutaro Uchimura, Makoto Nakamuta, Munechika Enjoji, Takashi Irie, Rie Sugimoto, Tatsushi Muta, Hiroaki Iwamoto, Hajime Nawata

    Activators of peroxisome proliferator–activated receptor γ (PPARγ), which forms a heterodimer with retinoic X receptor (RXR), inhibit the production of certain inflammatory mediators. To clarify the role of the PPARγ:RXR signaling pathway in Kupffer cells, we studied the effect of an RXR agonist and PPARγ agonist on LPS–induced nitric oxide (NO) and tumor necrosis factor–α (TNF–α) production. An RXR–specific agonist, Ro47–5944, and a PPARγ–specific agonist, AD4833 (pioglitazone hydrochloride), each inhibited LPS–induced NO and TNF–α production. The combined treatment of Ro47–5944 and AD4833 resulted in enhanced inhibition, and suppressed the mRNA levels of NO and TNF–α. PPARγ:RXR activation did not affect the level of LPS–induced phosphorylation of c–jun N–terminal kinase and p38 mitogen–activated protein kinase. PPARγ:RXR activation also did not affect nuclear factor kappa B (NF–κB) nuclear translocation nor NF–κB and activator protein 1 (AP–1) activation in the electrophoretic mobility–shift assay. Finally, PPARγ:RXR activation suppressed the LPS–induced promoter activity of the NF–κB–luciferase reporter gene in RAW 264.7 cells. These data imply that PPARγ:RXR activation suppresses LPS–induced NO and TNF–α production in Kupffer cells, and that this inhibition occurred at the transcriptional level. Although no consensus PPARγ:RXR–responsive element in the promoter regions of the inducible isoform of nitric oxide synthase (iNOS) and TNF–α genes was found, PPARγ:RXR may interfere with NF–κB and AP–1 transcriptional activity. Our data also suggest a potential therapeutic approach for moderating hepatic injury such as endotoxin shock in which Kupffer cell activation has been implicated.